•  

Posts Tagged: Centre of Excellence for Commercialization of Research (CECR program)

MaRS Innovation statement on the 2015 Federal Budget

TORONTO, ON (April 23, 2014) — MaRS Innovation congratulates the Federal Government’s deepened commitment to support Canadian research and innovation, particularly in the healthcare sector. In particular, the $42 million over five years dedicated to support the Canadian Centre for Aging and Brain Health Innovation at Baycrest Health Sciences, which includes $32 million in support from the Federal Economic Development Agency for Southern Ontario (FedDev). Baycrest is a founding member institution of MaRS Innovation. “As a Baycrest partner and long-time champions of the ... Read more

MaRS Innovation’s top 10 portfolio stories for 2014

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses. Here are our picks for the top 10 news stories from MaRS Innovation's portfolio. 1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study ... Read more

Accel-Rx Health Sciences Accelerator to Partner with BDC Venture Capital

MaRS Innovation co-partner in pan-Canadian effort to help create up to 20 leading start-up companies CEBIO International Conference, San Diego – June 25, 2014: BDC Venture Capital and the Accel-Rx Health Sciences Accelerator (Accel-Rx) announced today a collaboration to provide critical seed funding to new and emerging Canadian health sciences companies. This announcement was covered in TechVibes, PE HUB and BetaKit. Together, Accel-Rx, BDC Venture Capital, and CDRD Ventures Inc. (CVI) which will provide the initial management to launch Accel-Rx operations, would focus on ... Read more

MaRS Innovation’s 2013 Top 10 List

2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio. 1. MaRS Innovation secures a $15 million CECR funding extension In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada. This achievement reflects and recognizes the quality of the startups and licensable technologies within the MaRS Innovation portfolio, as well as the rigour of its business model and the achievements of its ... Read more

MaRS Innovation and Pfizer fund Bio-Manufacturing Technology

Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership. Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area. This announcement was covered by BetaKit. His technology generates cell lines with improved protein production and survival properties, important in the ... Read more

MaRS Innovation Announces Collaboration with Johnson & Johnson Innovation

Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health TORONTO, Nov. 25, 2013 - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics. This announcement was covered by Biotechnology Focus and the Village Gamer blog. Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly ... Read more

Dr. Hofstein’s Op-Ed for The Hill-Times, “Biotechnology research: A knowledge economy”

This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9: Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy. Canada has the holistic approach and translational research necessary to address health care’s pervasive ... Read more

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector. Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ... Read more

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed? MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ... Read more

Baxter and MaRS Innovation Form Strategic Partnership

Partnership to invest up to $1M in promising Canadian healthcare discoveries TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies. Information about Baxter and MaRS Innovation's partnership is also available in French. The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will ... Read more
Page 1 of 212